New Two-Drug attack on recurrent Women's cancers
NCT ID NCT06040970
Summary
This study aims to find the safest and most effective dose of a new drug, sacituzumab govitecan, when combined with an existing chemotherapy drug, cisplatin. It is for women whose ovarian or endometrial cancer has returned but responded well to platinum-based chemotherapy in the past. The research will first test for safety and then see how well the combination shrinks tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai Division of Hematology and Medical Oncology
RECRUITINGNew York, New York, 10029, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.